Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1153538 | 0.98 | MME (0.38) | MMELTA4HALDH1A1KCNK3THRB | |
| SCHEMBL1152846 | 0.96 | MME (0.35) | MMEALDH1A1KCNK3THRBCNR2 | |
| SCHEMBL1153446 | 0.92 | MME (0.33) | MMEALDH1A1KCNK3THRBCNR2 | |
| SCHEMBL1152942 | 0.81 | MME (0.37) | MMELTA4HCNR2CYP3A4CYP2C9 | |
| SCHEMBL1153744 | 0.79 | MME (0.36) | MMELTA4HCNR2CYP3A4CYP2C9 | |
| SCHEMBL1153869 | 0.78 | FPR3 (0.38) | MMEALDH1A1CNR2KMT2A | |
| SCHEMBL1153826 | 0.77 | MME (0.33) | MMECNR2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3541461 | 0.77 | FPR3 (0.37) | MMEALDH1A1CNR2KMT2A | |
| SCHEMBL1152945 | 0.77 | FPR3 (0.37) | MMEALDH1A1CNR2KMT2A | |
| SCHEMBL5384134 | 0.76 | CYP3A4 (0.37) | MMEALDH1A1KCNK3THRBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943799-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7842839-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070112201-A1 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1698617-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENE BISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112201-A1 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | CYP3A7, GRK7, CYP2A7 | MME 4743/4885LTA4H 617/4885ALDH1A1 610/4885 |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | CYP3A7, GRK7, CYP2A7 | MME 4743/4885LTA4H 617/4885ALDH1A1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.